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Abstract
Background: In recent years, early Endothelial Progenitor Cells (eEPCs) have been proven as effective tool in murine
ischemic AKI and in diabetic nephropathy. The mechanisms of eEPC-mediated vasoprotection have been elucidated in
detail. Besides producing a diverse range of humoral factors, the cells also act by secreting vasomodulatory microvesicles.
Only few data in contrast have been published about the role of so-called Endothelial Colony Forming Cells (ECFCs - late
EPCs) in ischemic AKI. We thus aimed to investigate ECFC effects on postischemic kidney function over several weeks. Our
special interest focused on endothelial-to-mesenchymal transition (EndoMT), peritubular capillary density (PTCD),
endothelial alpha-Tubulin (aT - cytoskeletal integrity), and endothelial p62 (marker of autophagocytic flux).
Methods: Eight to twelve weeks old male C57Bl/6 N mice were subjected to bilateral renal pedicle clamping for
35 or 45 min, respectively. Donor-derived syngeneic ECFCs (0.5 × 106) were i.v. injected at the end of ischemia.
Animals were analyzed 1, 4 and 6 weeks later.
Results: Cell therapy improved kidney function exclusively at week 1 (35 and 45 min). Ischemia-induced fibrosis
was diminished in all experimental groups by ECFCs, while PTCD loss remained unaffected. Significant EndoMT
was detected in only two of 6 groups (35 min, week 4 and 45 min, week 6), ECFCs reduced EndoMT only in the
latter. Endothelial aT declined under almost all experimental conditions and these effects were further aggravated
by ECFCs. p62 was elevated in endothelial cells, more so after 45 than after 35 min of ischemia. Cell therapy did
not modulate p62 abundances at any time point.
Conclusion: A single dose of ECFCs administered shortly post-ischemia is capable to reduce interstitial fibrosis in
the mid- to long-term whereas excretory dysfunction is improved only in a transient manner. There are certain
differences in renal outcome parameters between eEPCs and ECFC. The latter do not prevent animals from peritubular
capillary loss and they also do not further elevate endothelial p62. We conclude that differences between eEPCs and
ECFCs result from certain mechanisms by which the cells act around and within vessels. Overall, ECFC treatment was
not as efficient as eEPC therapy in preventing mice from ischemia-induced mid- to long-term damage.
Background
Endothelial Progenitor Cells (EPCs) are heterogeneous
in terms of origin and biological properties. A vast
amount of EPC-related literature has been accumulated
since their first description in 1997 [1]. Very early concepts
described the cells as substitutes of damaged mature endo-
thelial cells, suggesting a direct mechanism of vascular
repair [1–3]. However, our understanding of EPC biology
has fundamentally been changed over the last 10 years. It
has become evident that the cells are represented by at
least two major subpopulations, early and late Endothelial
Progenitor Cells (eEPCs/lEPCs). The fundamental differ-
ence between the two lies in the fact that eEPCs display
hematopoietic characteristics while lEPCs exclusively ex-
press endothelial but no hematopoietic marker molecules
[4]. Meanwhile lEPCs have been defined as ‘true’ progeni-
tors of endothelial cells, eEPCs in contrast should be rec-
ognized as ‘proangiogenic hematopoietic cells’ or simply as
‘proangiogenic cells’ (PACs) [5, 6].
Late EPCs may also be defined as Endothelial Colony-
Forming Cells (ECFCs) [4, 5, 7–12]. In contrast to
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eEPCs/PACs, ECFCs mediate vascular repair in a more
direct manner, by incorporating into the endothelial layer
of damaged blood vessels. Nevertheless, Burger and col-
leagues identified another mechanism of ECFC action.
Comparable to eEPCs, the cells secrete certain types of
exosomes which may prevent rats from AKI if adminis-
tered in a selective manner [7].
Acute kidney injury (AKI) remains a fundamental
problem in the field of intensive care medicine in Europe
and the US. Incidences and mortality rates have only
mildly been improved during the last 20 years [13]. AKI
patients suffer from significant short-term consequences
that evolve during the first days after onset of acute kidney
damage. Impaired excretion of water, solutes, and endogen-
ous toxins cause serious alterations of cardiovascular and
cerebral functions, respectively. The poor prognosis of AKI
also ensues from the underlying disease or etiology. Thus,
mortality may range from 30-50%, even if dialysis treatment
has been initiated [14]. Another problem that arises in the
mid- to long-term is an increased risk for chronic kidney
disease (CKD). AKI is regularly associated with a loss of
peritubular capillaries and the accumulation of connective
tissue in the interstitium [15–19]. As a matter of fact,
interstitial fibrosis better correlates with the risk of
CKD progression than glomerular sclerosis. The mech-
anisms perpetuating kidney fibrosis are complex and
different cell types have been shown to undergo a
process of mesenchymal transdifferentiation in CKD,
namely tubular epithelial cells (Epithelial-to-Mesenchymal
Transition – EMT [20]). Another source of mesenchymal
matrix proteins are mature endothelial cells within peritub-
ular vessels (capillaries, arterioles). Investigations performed
by the groups of Goligorsky and Kalluri [21, 22] revealed
Endothelial-to-Mesenchymal Transition (EndoMT) as rele-
vant cause of interstitial fibrosis in different disease models
of CKD. Investigations performed by our group confirmed
these findings [23, 24]. As a matter of fact, the prognosis of
AKI has not substantially been improved since the early
1990s, although a lot of progress has been achieved in the
fields of dialysis treatment and intensive care medicine.
Therefore new therapeutic strategies are urgently needed.
In recent years, stem/progenitor cell based therapies have
been studied more in detail and promising results were
acquired by using mesenchymal stem cells (MSCs [25, 26]).
Another interesting cell population is represented by
so-called induced pluripotent stem cells (iPS) [27–29].
Whether these or other cell-types will truly be estab-
lished as future therapeutic measures in AKI or not
remains debatable. Nevertheless, even if any transfer
of cell-based strategies should fail, scientists and clini-
cians can potentially acquire new knowledge about
AKI and possible therapeutic targets by studying the
mechanim of (stem/progenitor) cell-mediated AKI
protection.
EPCs, and in particular early EPCs have been used for
anti-ischemic treatment in numerous experimental disease
models, such as ischemic heart, cerebrovascular, and
peripheral artery disease, respectively [30–35]. In addition,
several studies showed the cells to be effective in experi-
mental AKI as well [36–38]. Own investigations focused
on strategies for improving efficacy of eEPC-treatment in
murine AKI. We were able to identify several substances
that are capable to augment renoprotective cell effects
[23, 39–42]. Lately, we analyzed mid-term consequences
of AKI treatment with a single dose of native eEPCs,
systemically applied at the time of reperfusion. The study
showed robust improvement of serum creatinine levels,
interstitial fibrosis, EndoMT and peritubular capillary dens-
ity [43]. Thus, EPCs have been established as reliable tool
in AKI in the short- and mid-term. It needs nevertheless to
be mentioned that endogenous early EPCs and ECFCs are
most likely not relevant for direct endothelial repair in AKI.
Sradnick and colleagues lately published a manuscript on
the topic which substantially questioned the role for extra-
renal progenitor cells in endothelial regeneration [44]. This
study however does not truly conflict with our past and the
current investigation(s) that primarily intend to establish
EPCs as therapeutic tool in AKI.
The data on ECFCs for AKI therapy are quite limited.
The only study performed so far was published by Burger
and colleagues [7]. We therefore aimed to investigate
ECFCs effects in murine ischemic AKI. Our particular
interest focused on parameters of interstitial kidney dam-
age, such as fibrosis, EndoMT, endothelial autophagy, and
endothelial alpha-tubulin, a marker of cytoskeletal integrity.
Methods
Animals models
As in previous investigations, the present animal study
protocol was in accordance with the guidelines of the
German Institute of Health Guide for the Care and Use
of Laboratory Animals and approved by the Institutional
Animal Care and Use Committee. All experiments were
performed in male, 8–12 weeks old C57BL/6 N mice,
which were originally obtained from Jackson Labs (Bar
Harbor, ME, USA) and bred in the local animal facility
of the Göttingen University Hospital. All animals were
separately caged with a 12:12-h light–dark cycle and had
free access to water and chow throughout the study.
Surgical procedures
The surgical procedure has extensively been performed
and published several times before [23, 43, 45]. We decided
to apply two different ischemic conditions (35 and 45 min)
in order to mimic AKI of different severity. Animals were
sacrificed (puncture of the heart and diaphragma cut) and
analyzed 1, 4, and 6 weeks later, respectively.
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Culture of mouse-derived early and late endothelial
progenitor cells
Early EPCs were cultured according to an established
protocol [43]. In detail, mononuclear cells (MNCs) were
enriched by density gradient centrifugation using Biocoll
solution (Biochrom, Berlin, Germany) from peripheral
blood and spleen cell extracts. MNCs were pooled from
blood and spleen in order to increase the total number
of cells available for therapy. Immediately following
isolation, mononuclear cells were mixed and 4 × 106
cells were plated on 24-well culture dishes coated with
human fibronectin (Sigma, St Louis, MO) and maintained
in endothelial cell medium-2 (EGM-2 - Clonetics, Lonza,
Walkersville, MD, USA) supplemented with endothelial
growth medium (EGM) Single-Quots containing 5%
FCS. For VE-Cadherin, CD14, and CD45 staining, cells
were grown on fibronectin-coated glass bottom slides,
the detailed procedure will be described below. After
4–5 days of culture, eEPCs were identified by the up-
take of DiI-labeled acetylated low-density lipoprotein
(acLDL) (Invitrogen, Carlsbad, CA, USA) and binding
of FITC-labeled BS-1 lectin (BS-1) (Sigma Diagnostics,
St. Louis, MO).
Late EPCs were cultured according to the following
procedure: peripheral mononuclear cells (4 × 106), iso-
lated by density centrifugation (see above) were cultured
on fibronectin-coated glass bottom slides in EGM-2 for
an average of 9 weeks. After washing the slides with PBS,
cells were fixated using 3.7% PFA in PBS for 15 min at
room temperature. After cell permeabilization with 0.1%
Triton X100 (20 min at room temperature) 1% milk
powder was applied for 30 min at room temperature.
Primary incubation was performed overnight at 4 °C
using the following antibodies: anti-mouse VE Cadherin,
host rabbit (Abcam, ab33168, 1:200), anti-mouse CD45,
host rat (Abcam, ab23910, 1:50), anti-mouse CD14, host
mouse (Abcam, ab182032, 1:100). After cell washing using
PBS, secondary incubation was performed for 1 h at
room temperature with the following antibodies: anti-
rabbit 488 (1:400), anti-rat 594 (1:400), anti-mouse 594
(1:400) (all secondary antibodies were purchased from
Jackson Dianova). Finally, the nuclei were stained with
DAPI solution.
Stained cells were analyzed using an inverted fluores-
cence microscope IX-71 (Olympus Deutschland GmbH,
Hamburg, Germany) equipped with the appropriate ex-
citation and emission filters (AHF Analysentechnik,
Tübingen, Germany). Images of respective fluorescence
channels were recorded as single high resolution 16bit
b/w images using a F-View II ext. Camera (Olympus
Deutschland GmbH, Hamburg, Germany). The images
from every fluorescence channel were then automatic-
ally merged using the MFIP-module of the CELL-F®
software.
Morphological analyses
The methodical procedures for quantification of fibrosis,
PTCD, EndoMT, and aT have been described in detail
recently [43]. Kidney fibrosis was examined in formalin
fixated, paraffin-embedded tissue sections after Masson
Trichrome staining. The amount of collagen deposition
(blueish area) was semiquantitatively assessed by assigning
grade 1 (mild), 2 (moderate) or 3 (severe). EndoMT and
endothelial aT were also evaluated in formalin fixated,
paraffin-embedded tissue sections after deparaffinization,
followed by incubation in 3% H2O2 for 10 min. After
citrate-buffer treatment (microwave, 5 times 3 min,
pH 6.0) sections were stained with rat anti-mouse CD31
(PECAM-1 - CloneSZ31, Dianova), and with either mouse
anti-acetylated alpha Tubulin (abcam - ab24610) or rabbit
anti-SMA (EMELCA) for primary incubation and with
Alexa Fluor 488 goat anti-rabbit IgG (Dianova), Alexa
Fluor 594 goat anti-rat IgG (Dianova), and Alexa Fluor
488 anti-mouse IgG (Dianova) for secondary incubation,
respectively. Primary incubation was performed overnight
at 4 °C while secondary incubation was performed for 1 h
at room temperature. p62 staining was performed as
described recently [45]. Rabbit anti p62 (abcam ab91526)
was used for primary incubation (4 °C, overnight),
followed by secondary incubation with anti rabbit 488
(Jackson ImmunoResearch) for one hour at RT. To
visualize the nuclei, tissue sections were counterstained
with DAPI. Three view fields per kidney were analyzed
for co-localization of either SMA, or aT, or p62 and
CD31 using ImageJ software. Confocal analyses were
performed with the Zeiss® LSM780 microscope and
with the Olympus® FLUOVIEW FV1000 microscope.
Renal function
Serum creatinine concentration was measured using a
commercially available kit (Creatinin, Jaffé, Labor und
Technik, Eberhard Lehmann, LT-CR0121, Berlin, Germany)
according to the manufacturer’s protocol.
Statistical analysis
The results were expressed as mean ± SEM. The means
of two populations were compared by Student’s t test.
Differences were considered significant at p < 0.05.
Results
In all analyzed categories, comparisons were made to
untreated control and to post-ischemic experimental
groups that have previously been used in another inves-
tigation related to early EPCs. The study has lately been
published separately in the American Journal of Physi-
ology – Renal Physiology [43].
Ten animals were included into each group, no ani-
mals died during follow-up.
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Phenotypical characteristics of syngeneic murine eEPCs
and lEPCs
Both, early and late EPCs were cultured according to
established protocols [7, 43]. In order to differentiate
between the two populations we defined early EPCs as
VE-Cadherin−/CD14+ or CD45+ cells and late EPCs as
VE-Cadherin+/CD14− or CD45− cells. This decision was
made in adaption to the observations by Burger and col-
leagues who detected neither CD14 nor CD45 on late
EPCs (ECFCs – Endothelial Colony Forming Cells [7]).
Figure 1 shows the results of fluorescence analysis. Early
EPCs expressed both hematopoietic markers (CD14 and
CD45), whereas VE-Cadherin was detected with very
low intensities. Late EPCs in contrast were strongly VE-
Cadhein positive but negative for the CD14 and CD45,
respectively.
Serum creatinine
The baseline serum creatinine in untreated controls was
0.23 ± 0.004 mg/dl. Postischemic creatinine levels sig-
nificantly increased under both experimental conditions
(35 and 45 min of ischemia). They remained elevated
throughout the whole period of post-ischemic analysis
(1, 4, and 6 weeks). Serum creatinine concentrations in
mg/dl: 35 min - 1 week(s) (w) 0.37 ± 0.01; 4 w 0.39 ±
0.008; 6 w 0.37 ± 0.008; 45 min - 1 w 0.42 ± 0.008; 4 w
0.36 ± 0.01; 6 w 0.38 ± 0.01. All p-values as compared to
controls were below 0.0001. Administration of a single
dose of 0.5 × 106 native syngeneic lEPCs at the end of
ischemia significantly improved serum creatinine levels
at week 1. This effect occurred after both, 35 and
45 min: 35 min 1 w + lEPCs 0.32 ± 0.01 (p-value vs. ische-
mia without cells 0.007); 45 min 1 w + lEPCs 0.38 ± 0.008
(p-value vs. ischemia without cells 0.01). Cell therapy did
not improve creatinine levels at later time points (4 and
6 weeks - numerical data not given). Figure 2 summarizes
the post-ischemic serum creatinine concentrations in all
experimental groups.
Interstitial fibrosis and EndoMT
Next, we aimed to analyze interstitial fibrosis and mesen-
chymal transdifferentiation of intrarenal endothelial cells
Fig. 1 Surface marker expression patterns of cultured late (lEPCs) as opposed to early Endothelial Progenitor Cells (eEPCs). Panel A depicts
combined staining of CD14 and VE-Cadherin, B shows staining of both cell types for CD45 and VE-Cadherin. Early EPCs expressed both hematopoietic
markers (CD14 and CD45) whereas VE-Cadherin was not detectable at all. Late EPCs in contrast were strongly VE-Cadhein positive but negative for the
other proteins, respectively (magnifications × 20 except the images behind the arrows: ×80; red in panel a: CD14, in panel b: CD45; green in both
panels: VE-Cadherin; blue in both panels: DAPI – nuclei; the white rectangles in panel b show magnified areas behind the arrows)
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(EndoMT), the latter being reflected by colocalization of
CD31 and aSMA in small peritubular arterioles [23, 24].
Fibrosis was assessed in a semiquantitative manner (arbi-
trary units).
Fibrosis: The baseline value in untreated controls was
1.0 ± 0.3. As a matter of fact, significant fibrosis occurred
under all experimental conditions at every time point:
35 min - 1 week(s) (w) 5.3 ± 2.3; 4 w 6.5 ± 0.9; 6 w 3.8 ±
0.6; 45 min - 1 w 7.1 ± 1.7; 4 w 10.8 ± 1.7; 6 w 14.8 ± 1.3.
The p-values as compared to controls were: 35 min – 1 w
0.04; 35 min – 4 w <0.0001; 35 min – 6 w 0.0004; 45 min –
1 w 0.002; 45 min – 4 w <0.0001; 45 min – 6 w <0.0001.
Cell therapy diminished matrix deposition under both
experimental conditions at every time point: 35 min -
1 w + lEPCs 1.1 ± 0.1; 4 w + lEPCs 1.5 ± 0.1; 6 w +
lEPCs 2.3 ± 0.2. The p-values for every time point were
(with vs. without cell administration): 1 w 0.04; 4 w <0.0001;
6 w 0.03; 45 min - 1 w+ lEPCs 2.8 ± 0.3; 4 w + lEPCs 2.7 ±
0.3; 6 w 2.8 ± 0.5; the p-values were: 1 w 0.01; 4 w <0.0001; 6
w <0.0001 (Fig. 3).
Although ischemia increased matrix deposition, EndoMT
(aSMA in CD31+ cells in %) was detected in a significant
manner only at week 4 in the 35 min group (12.6 ± 1.7% vs.
controls 4.9 ± 1.5%; p < 0.0001) and at week 6 in the 45 min
group (15.3 ± 1.9% vs. controls 4.9 ± 1.5%; p < 0.0001). Cell
treatment diminished EndoMT at 4 and 6 weeks but
exclusively in the 45 min group: 4 w + lEPCs 3.5 ±
0.9% and 6 w + lEPCs 3.5 ± 0.7%; the p-values vs.
ischemia without cell therapy were 4 w 0.01 and 6 w
0.0001. Figure 3 summarizes the results of mesenchy-
mal analysis.
Peritubular capillary density and endothelial alpha-Tubulin
Peritubular capillary rarefaction (PTCR) has been shown
to occur after ischemia and to promote progression
towards CKD [17, 18, 46]. PTCR was assessed by quantifi-
cation of peritubular CD31 immunofluorescence per area
(in %). Controls displayed a mean percentage of 4.8 ± 0.01.
PTCR declined under all experimental conditions with
one exception (35 min - 1 w): 35 min - 1 w 2.4 ± 0.8; 4 w
1.5 ± 0.2; 6 w 1.8 ± 0.5; 45 min - 1 w 1.7 ± 0.1; 4 w 1.7 ±
0.3; 6 w 1.3 ± 0.1. The p-values vs. controls were: 35 min -
1 w 0.09; 4 w 0.006; 6 w 0.02; 45 min - 1 w 0.001; 4 w
0.01; 6 w 0.001. Cell therapy did not modulate PTCR at
any time point, neither after 35 nor after 45 min of ische-
mia (Fig. 4).
In a recent study, endothelial acetylated alpha-Tubulin
(aT) has been proposed to serve as one possible marker
of endothelial cilia integrity [43], although it is not specific
for cilia but can also be detected in various other micro-
tubule structures. Flow-treatment of cultured mature endo-
thelial cells reduced percentages of cilia+ cells accompanied
by lower cellular abundances of aT. Cellular expression of
alpha-Smooth Muscle Actin (aSMA), a marker of mesen-
chymal transdifferentiation increased [43]. These effects
were completely reversible after incubation of the cells with
supernatant from untreated murine eEPCs. Analyses of
postischemic kidneys showed reduced EndoMT to parallel
with lower endothelial expression of aT as well. These
effects were partially augmented by cell treatment with
eEPCs [43]. Thus, lower endothelial aT was discussed to
reflect an ‘antifibrotic’ state. In the current study, dynamics
of endothelial aT were comparable to those mentioned in
the other study: endothelial aT declined under almost all
experimental conditions (results given as percentages of the
endothelial surface area, stained positive for aT; p-values
indicate differences as compared to controls; controls
51.5 ± 6.7%; 35 min - 1 w 34.4 ± 4.3%, p = 0.06; 35 min - 4
w 27.4 ± 2.4%, p = 0.007; 35 min - 6 w 23.5 ± 2.6%, p =
0.003; 45 min - 1 w 17.3 ± 2.1%, p = 0.0006; 45 min - 4 w
15.8 ± 2.2%, p = 0.0005; 45 min - 6 w 11.3 ± 2.6%, p =
0.0006), these effects were further aggravated by lEPC
treatment in all 35 min groups (p-values indicate dif-
ferences as compared to animals without cell therapy;
35 min - 1 w + lEPCs 8.2 ± 2.6%, p = 0.0004; 35 min - 4
w + lEPCs 8 ± 1.1%, p < 0.0001; 35 min - 6 w + lEPCs
12.4 ± 2%, p = 0.009) and in the 45 min group at week































































Fig. 2 Postischemic serum creatinine in all experimental groups (a: 35 min, b: 45 min). Renal ischemia significantly increased creatinine levels after
35 and 45 min of ischemia. Concentrations remained elevated throughout the whole postischemic period (until week 6). Systemic administration of
native lEPCs improved excretory kidney function exclusively at week 1 (35 and 45 min of ischemia) (Data as mean ± SEM, ✻: p < 0.05)






































































































Fig. 3 (See legend on next page.)
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Endothelial p62
In recent years, autophagy (AP) has increasingly been
recognized as endogenous mechanisms of cellular self-
defense. Recently, defective autophagy has been proposed
to aggravate EndoMT in cultured endothelial cells [47].
The methodical approaches for visualizing AP in cultured
cells/tissues have extensively been reviewed in the past
[48, 49]. AP involves several subcellular fusion events
ultimately resulting in the generation of autophagosomes
(APS). Several marker molecules for AP monitoring have
been established in the past, among those are LC3-II and
the protein p62. Increased AP is usually associated with in-
creased cellular abundance of LC3-II and lower availability
of p62 [50]. However, elevated p62 levels have also been
linked to increased flux through the autophagocytic cascade
[48, 50]. We therefore aimed to investigate endothelial p62
in all experimental groups. In comparison to untreated con-
trols endothelial p62 expression was significantly increased
in every experimental group post-ischemia (p-values show
differences as compared to controls; controls 2.9 ± 0.4%;
35 min - 1 w 6.9 ± 0.8%, p = 0.0003; 35 min - 4 w 5.2 ±
0.6%, p = 0.006; 35 min - 6 w 6.5 ± 0.6%, p < 0.0001;
45 min - 1 w 11.8 ± 1.9%, p < 0.0001; 45 min - 4 w 11.8 ±
0.8%, p < 0.0001; 45 min - 6 w 11 ± 1.3%, p < 0.0001). Sec-
ondly, endothelial p62 was lower in the 35 than in the
45 min groups at every given time point (35 min – 1 w vs.
45 min - 1 w p = 0.01; 35 min – 4 w vs. 45 min - 4 w p <
0.0001; 35 min – 6 w vs. 45 min - 6 w p = 0.002). Adminis-
tration of native lEPCs did not modulate endothelial p62
with one exception: 35 min - 1 w + lEPCs 3.2 ± 0.5%;
35 min - 4 w + lEPCs 4.8 ± 0.6%; 35 min - 6 w + lEPCs
6.4 ± 0.6%; 45 min - 1 w+ lEPCs 12.3 ± 1.6%; 45 min - 4 w+
lEPCs 10.8 ± 1.4%; 45 min - 6 w + lEPCs 11.4 ± 1.4%.
The p-value between 35 min - 1 w and 35 min - 1 w +
lEPCs was 0.008. Figure 5 summarizes the results.
Discussion
The current study is one of two investigations performed
so far that analyzed the therapeutic role of Endothelial
Colony Forming Cells (ECFCs) in experimental AKI. We
chose two different ischemic periods which were not
closely related to each other (35 and 45 min). We
intended to induce ischemic AKI of variable severity.
Nevertheless, the difference of 10 min may also allow
to speak about to different AKI entities (mild versus
moderate/severe AKI). In 2015, Burger and colleagues
[7] evaluated consequences of i.v. ECFC administration
in murine ischemic AKI, showing short-term (24 and
72 h) renoprotective effects of the cells. Similar results
were obtained by exclusively injecting ECFC-derived
exosomes. Our study was designed in order to analyze
AKI mid-term outcomes after injection of a single dose
of ECFCs at the time of reperfusion. We found improved
kidney function at week 1 after ischemia, diminished kidney
fibrosis in all experimental groups, significantly reduced
EndoMT in two of 6 groups (45 min, 4 and 6 weeks), no
preservation of PTCD at all, and decreased endothelial aT
levels in all of the 35 min but only in one of the 45 min
groups. Finally, endothelial p62, a marker of autophagocytic
flux was analyzed. Cell therapy did not modulate p62 at all.
We lately published a manuscript about the effectiveness of
early EPCs in the same context [43]. Effects on kidney func-
tion were comparable and kidney fibrosis was also dimin-
ished in (almost) all groups.
Nevertheless, some differences with regard to PTCD,
EndoMT, and endothelial aT shall be discussed. Firstly,
ECFCs as opposed to eEPCs were not capable to prevent
peritubular capillary loss. Several articles by Basile and
Goligorsky discussed PTCD loss as critical event in
AKI-related chronic kidney dysfunction [15–18, 46].
Cantaluppi and colleagues showed that EPC-derived
microvesicles alone may prevent the kidney from post-
AKI capillary rarefication, thus potentially reducing
the risk for chronic kidney disease (CKD) [36]. The
study by Burger et al. in contrast did not investigate
animals later than 72 h after the ischemic insult [7].
Before any conclusion may be drawn, regarding not
only PTCD but also EndoMT and endothelial aT abun-
dances it is important to discuss cellular mechanisms
of EPC(eEPC and lEPC) action within the (peri)vascular
microenvironment. The initial description of EPCs by
Asahara suggested a direct mechanism of vascular re-
pair [1]. According to this particular concept, cells
incorporate into the intimal layer of blood vessels in
order to substitute damaged mature endothelial cells.
Meanwhile, our understanding of EPC-mediated vaso-
protection has significantly been expanded. Early EPCs
predominantely act by indirect mechanims including
(See figure on previous page.)
Fig. 3 Renal fibrosis and EndoMT in the respective groups at 1, 4, and 6 weeks post-ischemia. As pointed out in the text, significant matrix deposition
occurred under all experimental conditions. In addition, cell administration reduced fibrosis after 35 and 45 min at weeks 1, 4, and 6, respectively (a – e).
f and g show the results of mesenchymal analysis. Significant EndoMT exclusively occurred in the 35 min group at week 4 and in the 45 min group at
week 6. Cell treatment reduced endothelial aSMA expression at week 4 (45 min) and at week 6 (45 min). Images (h - o) display detailed aSMA staining
patterns within the endothelium. h – k show endothelial and mesenchymal staining at 45 min with cell therapy (4 weeks), (l – o) depict the same staining
without cell administration. Images (n) and (o) allow to identify areas of CD31/aSMA co-expression in a detailed manner (white circles). In contrast, lEPC
therapy stabilized the endothelial-muscular borderzone distinctively. The latter was less accentuated in animals which did not receive any cells
at all (magnifications × 40 in c – e; ×160 in h - o; green in all microscopic images: aSMA; red: CD31; blue: nuclei; Data as mean ± SEM, ✻: p < 0.05)
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Fig. 4 Peritubular capillary density (PTCR) and endothelial alpha-Tubulin (aT) expression. PTCR was evaluated by measuring CD31 immunofluorescence per
cortical area. a and b show PTCR dynamics under the different experimental conditions with (a) for the 35 and B for the 45 min groups. In comparison to
the control group, ischemia significantly reduced PTCR in a prolonged manner (week 1 to 6). The only exception was the 35 min group at
week 1. Contrasting to earlier results published recently [43] late EPC therapy did not improve capillary densities in any of the groups. c – e
show representative images of CD31 analysis in controls as compared to two experimental groups. f and g show endothelial aT levels with
versus without lEPC therapy with (f) for the 35 and (g) for the 45 min groups. As mentioned in the text, endothelial aT decreased under all
experimental conditions with one exception: 35 min, week 1. Cell therapy further aggravated aT reduction with two exceptions: 45 min, weeks
4 and 6. h – q give detailed impressions of endothelial aT dynamics. h – l show single stained sections for aT (green – h), CD31 (red – i),
nuclei (blue – j), and RGB merge (all three colors – k) in the control group. l magnifies the white area in (k) fourfold. m – q display respective
single-stained sections from the 35 min 6 weeks + lEPC group (magnifications × 40 in c – e and in h – k/m - p; ×160 in l and q; yellow in k, l,

































Fig. 5 Endothelial p62 expression. Firstly, ischemia induced endothelial p62 in all experimental groups. Nevertheless, levels were always higher in
the 45 than in the 35 min groups. Secondly, cell therapy failed to modulate endothelial p62 at any given timepoint with the only exception of
35 min at week 1 (a). b – n display representative images from controls and several experimental groups. The white rectangle in (i) surrounds areas of
CD31/p62 colocalization. Images (k – n) show the results from confocal co-localization analysis with the respective monochromatic and one
merged image(s). k and n: p62 shows a punctuated staining pattern within CD31+ cells but also within adjacent vascular wall cells (magnifications ×
40 in b - i; ×160 in j; ×630 in k - n; green in all microscopic images: p62; red: CD31; yellow: CD31/p62 overlap; blue: nuclei; Data as mean ±
SEM, ✻: p < 0.05)
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the release of multiple humoral factors and of vaso-
modulatory microvesicles [4, 36, 51]. Vascular cell
incorporation occurs sporadically, this has been con-
firmed by own studies as well [39, 40]. In recent years,
early EPCs have therefore been proposed as hetergo-
geneous population of myelomonocytic cells or simply
as proangiogenic cells (PACs) [19]. ECFCs or late EPCs
on the other hand are most likely true progenitors of the
endothelium, characterized by significant vessel-formation
capacity both in vitro and in vivo [4, 52]. The lately pub-
lished study by Burger et al. [7] was the first to describe
indirect ECFC-mediated effects. Comparable to early
EPCs, ECFCs were shown to secrete certain types of small
vesicles (exosomes) which are capable to act tissue-
protective per se. Nevertheless, no study showed that the
cells act modulatory by producing humoral factors as well.
Such absence of a specific ´secretome´ may explain out-
come differences between eEPCs and ECFCs. In theory
one may argue that stabilization of the capillary network
predominantely results from indirect (humoral) effects of
EPCs and those are (to our knowledge) not mediated by
ECFCs. The same conclusion may be applicable with
regard to discrepancies in EndoMT and endothelial aT.
While early EPCs diminished EndoMT at week 4 post-
ischemia (35 min) and at week 6 (45 min), ECFCs reduced
mesenchymal transition at week 4 and 6 (45 min respect-
ively). ECFCs also reduced endothelial aT, even in more
groups than in the other study related to eEPCs [43]. In
our latest study [43] we proposed a dynamic cascade of
eEPC-mediated cytoskeletal (acetylated alpha-Tubulin)
reorganization with subsequent stabilization of the
endothelial ciliome, ultimately resulting in diminished
EndoMT. Although ECFCs reduced aT abundances in
even more groups that eEPCs, the current findings
partly support our previous hypothesis. Nevertheless,
it appears premature to generally propose reduced
endothelial levels of acetylated aT as endothelial-protective
mechanism. An association between endothelial aT and
EndoMT may exist, but a mechanistic relationship between
aT and EndoMT/reduction of endothelial dysfunction in
AKI cannot be claimed with certainty at the moment.
Further studies must particularly address dynamics of
endothelial aT and functional alterations such as endo-
thelial permeability and viability.
Endothelial p62 increased after ischemia with even more
intensive staining patterns after 45 min of ischemia. Similar
findings have been reported in another study from 2015
[45]. The protein p62 has been suggested as marker of
autophagocytic flux [48]. As opposed to eEPCs [45], ECFCs
did not further increase endothelial p62. There was no
difference between ischemia without and ischemia with
cell therapy. In addition, there was no association between
p62 dynamics and cell-mediated modulation of EndoMT.
Whether in our study elevated endothelial p62 reflected a
persistently increased flux through the autophagocytic
cascade or not remains debatable at the moment. Regard-
ing our findings, it is however impossible to conclude that
both events, autophagy and EndoMT were significantly
linked to each other since cell therapy inhibited EndoMT
while p62 remained unaffected. We once again suppose
that differences between eEPC- and ECFC-mediated
effects on parameters of endothelial integrity most likely
result from differences in cellular mechanisms of action.
Current own investigations extensively analyze the secre-
tome of eEPCs and are also intended to identify paracrinice
effects of ECFCs. We thus hope to further clarify some
discrepancies between the two studies.
Our general conclusion is that ECFCs are capable to
protect the postischemic kidney from persistent damage.
We must nevertheless also conclude that the cells per se
are less potent than eEPCs in this context. Particularly
the missing effects on PTCD are critical in terms of
CKD-progression. The differences between eEPCs and
ECFCs are most likely attributed to the individual mecha-
nisms by which these cells act around and within vessels.
A deeper understanding of the processes involved will
hopefully help to introduce EPCs or exclusively the cells’
modes of action (humoral factors, microvesicular struc-
tures) into the therapeutic AKI management. Finally, it
has to be mentioned that in the current study cells were
injected only once. The process of postischemic kidney
repair may last for several days to weeks (or even months).
Further studies are needed to evaluate the efficacy of alter-
native cell administration protocols (e.g. cell injection
prior to and post-ischemia, repeated cell injection after
ischemia). In addition, a transgenic model of constitutive
endothelial cell tracing could serve as tool for assessing
engraftment of early EPCs and ECFCs in the ‘therapeutic
situation’.
Conclusions
Our general conclusion is that a single dose of ECFCs
administered shortly post-ischemia is capable to reduce
interstitial fibrosis in the mid- to long-term whereas
excretory dysfunction is improved only in a transient
manner.
We must nevertheless also conclude that the cells per
se are less potent than eEPCs in this context. Particularly
the missing effects on PTCD are critical in terms of
CKD-progression.
The differences between eEPCs and ECFCs are most
likely attributable to the individual mechanims by which
the cells act around and within vessels.
Regarding the previous conclusion we particularly
conclude that eEPCs most likely exihibt stronger indirect
effects, mediated by microvesicles/certain humoral factors.
These may account for discrepancies between outcome
parameters (EndoMT, aT, p62).
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A deeper understanding of the processes involved will
hopefully help to intro- duce EPCs or exclusively the
cells’ modes of action (humoral factors, microvesicular
structures) into the therapeutic AKI management.
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